- American Thyroid Association (ATA) classification, age, and preablation stimulated thyroglobulin (sTG) levels are associated with 10-year survival in patients with differentiated thyroid cancer (DTC), according to a retrospective study.
Why this matters
- Relatively few studies have analyzed OS rates and associated prognostic factors for patients with DTC.
- Multivariate factors for reduced 10-year OS:
- Initial ATA high (OR, 21.9; 95% CI, 8.5-56.3) or intermediate (OR, 4.7; 95% CI, 2.9-7.5) recurrence risk classification.
- Age 45-55 years (OR, 4.9; 95% CI, 2.7-8.7) or >55 years (OR, 23.8; 95% CI, 7.5-75.3).
- Preablation sTG ≥30 μg/L (OR, 8.4; 95% CI, 4.6-15.3).
- Patients were stratified into 3 groups on the basis of these factors and associated survival:
- Excellent: 10-year OS of 99% in patients
- Moderate: 10-year OS of 94.5% in patients
- Low: 10-year OS of 49% in patients ≥55 years with preablation sTG ≥30 μg/L.
- 1093 patients with DTC who received radioactive iodine ablation after thyroidectomy were included.
- Funding: None.
- Retrospective study design.